This is a published notice on the Find a Tender service: <a href="https://www.find-tender.service.gov.uk/Notice/000565-2022">https://www.find-tender.service.gov.uk/Notice/000565-2022</a>

Tender

# **Supply of Aseptically Prepared Dose Banded Medicines**

HealthTrust Europe LLP (HTE) acting as agent for the University Hospitals of Coventry and Warwickshire NHS Trust ("UHCW")

F02: Contract notice

Notice identifier: 2022/S 000-000565

Procurement identifier (OCID): ocds-h6vhtk-0308cd

Published 7 January 2022, 10:45pm

# **Section I: Contracting authority**

### I.1) Name and addresses

HealthTrust Europe LLP (HTE) acting as agent for the University Hospitals of Coventry and Warwickshire NHS Trust ("UHCW")

19 George Road

Edgbaston, Birmingham

**B15 1NU** 

#### **Email**

Neli.Raleva@htepg.com

### **Telephone**

+44 08458875000

### Country

**United Kingdom** 

### **NUTS** code

UK - United Kingdom

### Internet address(es)

Main address

https://healthtrusteurope.bravosolution.co.uk

### I.3) Communication

Access to the procurement documents is restricted. Further information can be obtained at

https://healthtrusteurope.bravosolution.co.uk

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

https://healthtrusteurope.bravosolution.co.uk

Tenders or requests to participate must be submitted to the above-mentioned address

# I.4) Type of the contracting authority

Ministry or any other national or federal authority

# I.5) Main activity

Health

# **Section II: Object**

### II.1) Scope of the procurement

### II.1.1) Title

Supply of Aseptically Prepared Dose Banded Medicines

Reference number

SF051571

### II.1.2) Main CPV code

• 33600000 - Pharmaceutical products

### II.1.3) Type of contract

Supplies

### II.1.4) Short description

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.1.5) Estimated total value

Value excluding VAT: £3,500,000,000

### II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

The contracting authority reserves the right to award contracts combining the following lots or groups of lots:

one or more Lots

### II.2) Description

### II.2.1) Title

#### **BORTEZOMIB**

Lot No

1.1

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2) Description

### II.2.1) Title

**CARBOPLATIN** 

Lot No

1.2

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions

• 85149000 - Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2) Description

II.2.1) Title

**CETUXIMAB** 

Lot No

1.3

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2) Description

II.2.1) Title

**CISPLATIN** 

Lot No

#### 1.4

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## II.2) Description

### II.2.1) Title

### **CYCLOPHOSPHAMIDE**

Lot No

1.5

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

**Duration in months** 

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2) Description

### II.2.1) Title

#### **CYTARABINE**

Lot No

1.6

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# II.2) Description

### II.2.1) Title

**DESFERRIOXAMINE** 

Lot No

1.7

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions

• 85149000 - Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2) Description

II.2.1) Title

DOCETAXEL

Lot No

1.8

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

# II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2) Description

### II.2.1) Title

**DOXORUBICIN** 

Lot No

#### 1.9

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## II.2) Description

### II.2.1) Title

**EPIRUBICIN** 

Lot No

1.10

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

**Duration in months** 

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2) Description

### II.2.1) Title

#### **FLUOROURACIL**

Lot No

1.11

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# II.2) Description

### II.2.1) Title

**GANCICLOVIR** 

Lot No

1.12

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions

• 85149000 - Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2) Description

### II.2.1) Title

### **GEMCITABINE**

Lot No

1.13

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

INO

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# II.2) Description

### II.2.1) Title

**INFLIXIMAB** 

Lot No

#### 1.14

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## II.2) Description

### II.2.1) Title

**IRINOTECAN** 

Lot No

1.15

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

NUTS codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2) Description

### II.2.1) Title

#### **METHOTREXATE**

Lot No

1.16

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# II.2) Description

### II.2.1) Title

**NIVOLUMAB** 

Lot No

1.17

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions

• 85149000 - Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2) Description

II.2.1) Title

**OXALIPLATIN** 

Lot No

1.18

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

# II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2) Description

### II.2.1) Title

**PACLITAXEL** 

Lot No

#### 1.19

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## II.2) Description

### II.2.1) Title

### **PEMBROLIZUMAB**

Lot No

1.20

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

### II.2) Description

### II.2.1) Title

#### **PERTUZUMAB**

Lot No

1.21

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

## II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# II.2) Description

### II.2.1) Title

**RITUXIMAB** 

Lot No

1.22

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions

• 85149000 - Pharmacy services

#### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

#### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

#### II.2.6) Estimated value

Value excluding VAT: £100,000,000

#### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

#### II.2.10) Information about variants

Variants will be accepted: No

#### II.2.11) Information about options

Options: No

#### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# II.2) Description

II.2.1) Title

TRASTUZUMAB SC

Lot No

1.23

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

#### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

#### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

#### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

#### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# II.2) Description

### II.2.1) Title

TRASTUZUMAB IV

Lot No

#### 1.24

#### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

#### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

#### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

#### II.2.6) Estimated value

Value excluding VAT: £100,000,000

#### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# II.2) Description

### II.2.1) Title

**VINCRISTINE** 

Lot No

1.25

#### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33692000 Medical solutions
- 85149000 Pharmacy services

#### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

#### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

#### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

#### II.2.6) Estimated value

Value excluding VAT: £100,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

**Duration in months** 

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

#### II.2.10) Information about variants

Variants will be accepted: No

#### II.2.11) Information about options

Options: No

# II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# II.2) Description

#### II.2.1) Title

Aseptically Prepared Dose Banded Medicines

Lot No

2

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33680000 Pharmaceutical articles
- 85149000 Pharmacy services

#### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

#### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

#### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

#### II.2.6) Estimated value

Value excluding VAT: £500,000,000

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

#### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# II.2) Description

### II.2.1) Title

**CIVAS** 

Lot No

3

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33680000 Pharmaceutical articles

• 85149000 - Pharmacy services

#### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

#### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

#### II.2.6) Estimated value

Value excluding VAT: £200,000,000

#### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

#### II.2.10) Information about variants

Variants will be accepted: No

#### II.2.11) Information about options

Options: No

#### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# II.2) Description

#### II.2.1) Title

Patient Specific Chemotherapy

Lot No

4

### II.2.2) Additional CPV code(s)

- 33600000 Pharmaceutical products
- 33680000 Pharmaceutical articles
- 85149000 Pharmacy services

#### II.2.3) Place of performance

**NUTS** codes

• UK - United Kingdom

#### II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

#### II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

### II.2.6) Estimated value

Value excluding VAT: £300,000,000

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.

### II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# Section IV. Procedure

# **IV.1) Description**

### IV.1.1) Type of procedure

Open procedure

### IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

### IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

# IV.2) Administrative information

### IV.2.2) Time limit for receipt of tenders or requests to participate

Date

14 February 2022

Local time

12:00pm

### IV.2.4) Languages in which tenders or requests to participate may be submitted

**English** 

#### IV.2.7) Conditions for opening of tenders

Date

14 February 2022

Local time

12:01pm

# **Section VI. Complementary information**

# VI.1) Information about recurrence

This is a recurrent procurement: No

# VI.3) Additional information

TERMS AND CONDITIONS / ACTIVITY BASED INCOME (ABI)

The terms and conditions of this Framework Agreement is appended to the ITT. These terms include provisions requiring the payment by the supplier of an ABI management charge in consideration of the award of this Framework Agreement, the management and administration by HTE of the overall contract structure and associated documentation, as well as the requirement to submit regular management information to HTE.

SUBMISSION OF EXPRESSIONS OF INTEREST AND PROCUREMENT INFORMATION.

This exercise will be conducted on the HTE Bravo portal. Candidates wishing to be considered must register expressions of interest as follows:

Register on the HTE portal at <a href="https://healthtrusteurope.bravosolution.co.uk">https://healthtrusteurope.bravosolution.co.uk</a>. Login to the portal with username/password. Click the SQs/ITTs Open to All Suppliers link. These are the SQs/ITTs open to any registered supplier. Click on the relevant SQs/ITT to access the content. Click the Express Interest button at the top of the page. This will move the SQs/ITT into your My SQs/My ITTs page. You can access any attachments by clicking Buyer Attachments in the SQs/ITT Details box. Follow the onscreen instructions to complete the SQs/ITT. Submit your reply using the Submit Response button at the top of the page. If you

require any further advice, contact the Bravo e-Tendering Help Desk at <a href="help@bravosolution.co.uk">help@bravosolution.co.uk</a>.

#### Sid4Gov

HTE utilises the sid4gov supplier information database. Candidates should register on sid4gov at <a href="https://sid4gov.cabinetoffice.gov.uk/organisation/register">https://sid4gov.cabinetoffice.gov.uk/organisation/register</a> and submit their sid4gov company profile for publication on the database. Candidates already registered on sid4gov must ensure information is up to date.

Where access to sid4gov is unavailable, please contact the sid4gov helpdesk at sid4gov@gps.gsi.gov.uk.

Please note that sid4gov does not prepopulate any fields of the SQ on HTE's Bravo Portal. Candidates must complete the Qualfication & Technical envelopes of the SQ on Bravo in full.

# VI.4) Procedures for review

# VI.4.1) Review body

Legal Department

19 George Road

Birmingham

**B15 1NU** 

Country

**United Kingdom**